Although the model was originally developed in a NSCLC cohort, where PD-L1 status is a gold standard, a widely accepted biomarker used in the clinical routine for treatment decision, it was tested on a pan-cancer cohort with advanced patients from clinical trials. Here, CD274 is linked to non-small cell lung carcinoma.